Ratiopharm in Sweden: Exploiting Electronics
Increasingly competitive generics markets are forcing companies to be as creative as they can in securing even a few weeks' head-start over competitors. Ratiopharm is exploiting Swedish GPs' widespread use of electronic prescription systems to circumnavigate a timing quirk in the country's substitution law and gain vital market share for its generic omeprazole.
You may also be interested in...
Germany's Schwarz has invested heavily in its transition from a marketing organization into a development-based firm. Higher-than expected windfall revenues from generic omeprazole increase its chances of a successful transformation.
Verona Pharma’s Phase III ensifentrine, if approved, would be the first new dual-mechanism treatment class for COPD patients in decades. It could propel the UK-based biotech toward profitability, or into the arms of a larger partner.
Germany is drastically squeezing orphan drug pricing while new US laws protect rare diseases drugs from price negotiations. These contrasting moves fuel the longstanding debate over whether orphans still deserve special incentives.